Paser Related Published Studies
Well-designed clinical trials related to Paser (Aminosalicylic Acid)
Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. [2007.09]
Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. [2007.07.01]
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. [2006.01]
Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. [2005.06.01]
Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial. [2004.12]
Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. [2003.10]
Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. [2003.05.01]
The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. [2003.01]
Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. [2002.11]
Comparison between nasal and intravenous desmopressin for the treatment of aminosalicylic acid-induced platelet dysfunction. [2002.09]
Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. [2002.02]
Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. [2001.11]
Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis. [2000.09]
The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. [1999.03]
Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. [1997.10]
Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. [1997.07]
Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. [1996.11]
Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. [1996.08]
Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. [1996.06]
Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission. [1996.04]
Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. [1995.12]
Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. [1995.10]
Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. [1995.10]
A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. [1995.04]
Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis. [1994.09]
Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis. [1994.08]
Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. [1994.06]
Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). [1994.02]
Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. [1994.01]
Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience. [1994]
Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease. [1993.08]
Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. [1993.05]
A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. [1993]
Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. [1992.08]
Double blind, controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis. [1992.07]
A prospective randomized double blind trial comparing prednisolone and 4-aminosalicylic acid enemas in acute distal ulcerative colitis. [1992.03]
Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA). [1992.02]
Topical 5-aminosalicylic acid: a treatment for aphthous ulcers. [1992.02]
Placebo-controlled trial of ulcerative colitis with oral 4-aminosalicylic acid. [1992.02]
[5-aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenetic proctosigmoiditis. A comparative randomized multicenter trial] [1992]
Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. [1991.08]
Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. [1990.11]
5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. [1990.09]
Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity. [1990.09]
Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. [1990.07]
Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. [1990.05]
Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. [1990.05]
Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. [1989.08]
Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. [1989.04]
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. [1989.01.14]
Comparison of 5-aminosalicylic acid (3 g) and prednisolone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis. A prospective, randomized, double-blind trial. [1988.10]
5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? [1988.08]
Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. [1988.06]
Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. [1988.05]
5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. [1988.04]
Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial. [1988.02]
Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. [1988.02]
Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. [1988.01]
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. [1987.12.24]
[Unwanted side-effects in using mesalazine (5-aminosalicylic acid) during radiotherapy] [1987.10]
5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. [1987.09]
Well-designed clinical trials possibly related to Paser (Aminosalicylic Acid)
Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. [2008.10]
Is rosiglitazone a promising treatment for ulcerative colitis? [2008.09]
N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized, placebo-controlled pilot study. [2008.05.14]
Interventions for treating lymphocytic colitis. [2008.04.16]
A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. [2008.01.07]
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. [2007.12]
Successful Treatment of Steroid Refractory Active Ulcerative Colitis with Natural Interferon-beta - an Open Long-Term Trial. [2007.12]
Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. [2007.11.01]
Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-up. [2007.11]
Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. [2007.10]
A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. [2007.07]
Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. [2007.06.15]
Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. [2007.06]
Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study. [2007.04]
Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. [2007.03]
Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. [2007.03]
Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. [2007.02]
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. [2007.01]
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. [2007.01]
Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? [2007]
Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. [2006.12]
[Characterization of proteinuria in patients with ulcerative colitis and therapy with aminosalicylates] [2006.10.15]
Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. [2006.10.01]
[A clinical trial of rosiglitazone and 5-aminosalicylate combination for ulcerative colitis] [2006.07]
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. [2006.06.01]
Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study. [2006.05.15]
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. [2006.05.15]
Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. [2006.04.01]
Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. [2006.04]
Routine surgery in addition to chemotherapy for treating spinal tuberculosis. [2006.01.25]
Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients. [2006.01]
Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: A double-blind, randomized, placebo-controlled study. [2005.12.07]
Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients. [2005.12.01]
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. [2005.11]
A randomized trial of nicotine enemas for active ulcerative colitis. [2005.11]
Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. [2005.07]
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. [2005.07]
Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. [2005.05.01]
Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. [2005.05.01]
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. [2005.05]
|
